Drug Patents owned by Daiichi Sankyo Inc
1. List of Morphabond Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7955619 | DAIICHI SANKYO INC | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
| US10314788 | DAIICHI SANKYO INC | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 02 October, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
2. List of Savaysa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7365205 | DAIICHI SANKYO INC | Diamine derivatives |
Apr, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9149532 | DAIICHI SANKYO INC | Pharmaceutical composition |
Mar, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Aug 9, 2022 |
Drugs and Companies using EDOXABAN TOSYLATE ingredient
Market Authorisation Date: 08 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
3. List of Turalio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
| US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
| US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(10 years from now) | |
| US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
| US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(5 years from now) | |
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(10 years from now) | |
| US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
| US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) | |
| US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) | |
| US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 2, 2024 |
| Orphan Drug Exclusivity (ODE) | Aug 2, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 02 August, 2019
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
4. List of Welchol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7229613 | DAIICHI SANKYO INC | Method for lowering serum glucose |
Apr, 2022
(9 months ago) | |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2019
Treatment: A method for reducing serum glucose levels in adults with type 2 diabetes mellitus
Dosage: BAR, CHEWABLE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic